Silence Therapeutics Future Growth
Future criteria checks 2/6
Silence Therapeutics's earnings are forecast to decline at 3.1% per annum while its annual revenue is expected to grow at 31.4% per year. EPS is expected to grow by 19.3% per annum. Return on equity is forecast to be -82.2% in 3 years.
Key information
-3.1%
Earnings growth rate
19.3%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 31.4% |
| Future return on equity | -82.2% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 17 | -91 | -76 | N/A | 4 |
| 12/31/2025 | 28 | -78 | -64 | N/A | 6 |
| 12/31/2024 | 21 | -63 | -51 | N/A | 6 |
| 9/30/2024 | 16 | -59 | N/A | N/A | N/A |
| 6/30/2024 | 18 | -40 | -29 | -29 | N/A |
| 3/31/2024 | 26 | -35 | -39 | -39 | N/A |
| 12/31/2023 | 25 | -43 | -39 | -39 | N/A |
| 9/30/2023 | 28 | -43 | -41 | -41 | N/A |
| 6/30/2023 | 29 | -41 | -46 | -45 | N/A |
| 3/31/2023 | 23 | -43 | -39 | -39 | N/A |
| 12/31/2022 | 18 | -40 | -46 | -45 | N/A |
| 9/30/2022 | 16 | -36 | -35 | -34 | N/A |
| 6/30/2022 | 16 | -39 | -31 | -30 | N/A |
| 3/31/2022 | 15 | -39 | 3 | 5 | N/A |
| 12/31/2021 | 12 | -39 | 5 | 7 | N/A |
| 9/30/2021 | 11 | -42 | 3 | 4 | N/A |
| 6/30/2021 | 10 | -42 | 2 | 2 | N/A |
| 3/31/2021 | 8 | -35 | -24 | -23 | N/A |
| 12/31/2020 | 5 | -33 | -11 | -11 | N/A |
| 9/30/2020 | 3 | -26 | 0 | 1 | N/A |
| 6/30/2020 | 1 | -22 | 12 | 13 | N/A |
| 3/31/2020 | 1 | -21 | 7 | 7 | N/A |
| 12/31/2019 | 0 | -20 | 2 | 2 | N/A |
| 9/30/2019 | 0 | -19 | -8 | -8 | N/A |
| 6/30/2019 | N/A | -18 | -18 | -18 | N/A |
| 3/31/2019 | N/A | -18 | -18 | -18 | N/A |
| 12/31/2018 | N/A | -18 | -17 | -17 | N/A |
| 9/30/2018 | N/A | -12 | -15 | -15 | N/A |
| 6/30/2018 | N/A | -5 | N/A | -14 | N/A |
| 3/31/2018 | 0 | -3 | N/A | -12 | N/A |
| 12/31/2017 | 0 | -2 | N/A | -10 | N/A |
| 9/30/2017 | 0 | -5 | N/A | -9 | N/A |
| 6/30/2017 | 1 | -9 | N/A | -9 | N/A |
| 3/31/2017 | 1 | -9 | N/A | -9 | N/A |
| 12/31/2016 | 1 | -8 | N/A | -10 | N/A |
| 9/30/2016 | 0 | -8 | N/A | -10 | N/A |
| 6/30/2016 | N/A | -7 | N/A | -9 | N/A |
| 3/31/2016 | N/A | -7 | N/A | -9 | N/A |
| 12/31/2015 | N/A | -7 | N/A | -8 | N/A |
| 9/30/2015 | 0 | -8 | N/A | -9 | N/A |
| 6/30/2015 | 0 | -10 | N/A | -9 | N/A |
| 3/31/2015 | 0 | -10 | N/A | -9 | N/A |
| 12/31/2014 | 0 | -11 | N/A | -9 | N/A |
| 9/30/2014 | 0 | -11 | N/A | -9 | N/A |
| 6/30/2014 | 0 | -11 | N/A | -9 | N/A |
| 3/31/2014 | 0 | -10 | N/A | -8 | N/A |
| 12/31/2013 | 0 | -9 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SLNC.F is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SLNC.F is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SLNC.F is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SLNC.F's revenue (31.4% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: SLNC.F's revenue (31.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SLNC.F is forecast to be unprofitable in 3 years.